Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Mar 4, 2010

Premium

Title: microRNA Expression Abnormalities of Pancreatic, Endocrine, and Acinar Tumors

Patent Number: 7,670,840

Filed: Jan. 3, 2007 PCT Filed: Jan. 3, 2007

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent's abstract states, "provides novel methods and compositions for the diagnosis, prognosis, and treatment of pancreatic cancer. The invention also provides methods of identifying anti-pancreatic cancer agents."


Title: Inhibition of Brain Enzymes Involved in Cerebral Amyloid Angiopathy and Macular Degeneration

Application Number: 20100047336

Filed: Aug. 17, 2009

Lead Inventor: Wolff Kirsch, Loma Linda University Medical Center

The patent application, its abstract states, claims "a method of treating or inhibiting progress of dementia and/or macular degeneration in a mammal [by] administering compositions containing siRNA to heme oxygenase-1 or heme oxygenase-2, a matrix metalloproteinase inhibitor, a caspase inhibitor, or a metalloporphyrin in a manner that permits access to brain sites and/or the macula of the patient."


Title: Method for Detecting Nucleic Acids

Application Number: 20100047784

Filed: June 29, 2007 PCT Filed: June 29, 2007

Lead Inventor: Gilad Shlomit, Rosetta Genomics

The patent application, its abstract states, claims "methods and compositions for detecting, amplifying, and labeling targeted nucleic acids, including microRNAs."


Title: Nucleic Acid Compounds for Inhibiting VEGF Family Gene Expression and Uses Thereof

Application Number: 20100047909

Filed: Feb. 28, 2008 PCT Filed: Feb. 28, 2008

Lead Inventor: Steven Quay, MDRNA

The invention, the patent application's abstract states, comprises "meroduplex ribonucleic acid molecules capable of decreasing or silencing one or more VEGF family gene expression. An mdRNA of this disclosure comprises at least three strands that combine to form at least two non-overlapping double-stranded regions separated by a nick or gap wherein one strand is complementary to one or more VEGF family mRNA. In addition, the meroduplex may have at least one uridine substituted with a 5-methyluridine and optionally other modifications or combinations thereof. Also provided are methods of decreasing expression of one or more VEGF family gene in a cell or in a subject to treat one or more VEGF family-related disease."


Title: siRNA Targeting Tumor Protein 53

Application Number: 20100048425

Filed: Sept. 18, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."


Title: Stable and Long-Lasting siRNA Expression Vectors and the Applications Thereof

Application Number: 20100048670

Filed: Feb. 14, 2006 PCT Filed: Feb. 14, 2006

Lead Inventor: Denis Biard, Commissariat a l'Energie Atomique

"The invention relates to a siRNA expression vector that can inhibit or eliminate the expression of a target gene in a mammalian cell," the patent application's abstract states. "The invention also relates to the applications of one such expression vector."


Title: Compositions for Transfection of Oligonucleotides Active for Gene Silencing and Their Biological and [Therapeutic] Applications

Application Number: 20100048672

Filed: April 5, 2007 PCT Filed: April 5, 2007

Lead Inventor: Patrick Neuberg, Polyplus Transfection

"The invention relates to compositions of transfection comprising an oligonucleotide and an amphiphilic cationic molecule of formula," the patent application's abstract states. "The invention relates to compositions active for oligonucleotides delivery into eukaryotic cells in culture, ex vivo or in vivo. The invention [also] relates to compositions of transfection comprising an oligonucleotide active for RNA interference. Such compositions can be used as tools for biological studies or as drugs for therapies."


Title: Role of miRNA in T Cell Leukemia

Application Number: 20100048674

Filed: June 8, 2009

Lead Inventor: Chang-Zheng Chen, Stanford University

"The ability of miR-181a to support active signaling between Notch and pre-TCR pathways by coordinately dampening negative regulators of these pathways allows the use of miR-181a as a therapeutic target for T-ALL," the patent application's abstract states.


Title: miRNA Triplex Formations for the Down-Regulation of Viral Replication

Application Number: 20100048675

Filed: July 30, 2009

Inventor: Omar Bagasra, Claflin University

"As discovered herein, using miRNAs having high homology with both HIV-1 and a co-infecting virus such as HHV-6, HHV-7, or GVB-C, one can inhibit viral replication, more particularly HIV-1 replication, using such mutually homologous miRNAs that give rise to the creation of stable triplex formations effective in the down-regulation and/or inhibition of viral replication," the patent application's abstract states.


Title: microRNA-Based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Acute Myeloid Leukemia

Application Number: 20100048681

Filed: Jan. 29, 2008 PCT Filed: Jan. 29, 2008

Inventor: Carlo Croce, Ohio State University

The invention comprises "novel methods and compositions for the diagnosis, prognosis, and treatment of acute myeloid leukemia," the patent application's abstract states. "The invention also provides methods of identifying anti-AML agents."


Title: Lipid Nanoparticle-Based Compositions and Methods for the Delivery of Biologically Active Molecules

Application Number: 20100048888

Filed: Oct. 17, 2007 PCT Filed: Oct. 17, 2007

Lead Inventor: Tongqian Chen, Merck

The invention, the patent application's abstract states, "relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of gene expression and/or activity in a subject or organism.

"Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles, and transfection agents that effectively transfect or deliver biologically active molecules, such as … dsRNA … and small nucleic acid molecules, such as short interfering nucleic acids… to relevant cells and/or tissues, such as in a subject or organism," the abstract adds. "Such novel cationic lipids, microparticles, nanoparticles, and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism."

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.